Health technology company Royal Philips and genome data sequencing tools provider Illumina have partnered to offer integrated genomics solutions for oncology.
The collaboration intends to use Illumina’s DNA sequencing technology and BaseSpace Sequence Hub with Philips’ cloud-based genomics platform for the acquisition, analysis and interpretation of genomics data in cancer research.
The companies will also seek to engage in clinical research collaborations with health systems in the US that plan to develop precision medicine programs in oncology.
The integrated solution will combine data from multiple sources including radiology, immunohistochemistry, digital pathology, medical records and lab tests and will be shown in a consolidated view.
This system will support researchers to develop insights more efficiently and will support in cutting down health care costs and improved health outcomes.
Philips Connected Care and Health Informatics CEO Jeroen Tas said: “Until now the ability to use genomic data with the aim of having a precise diagnosis of cancer and improve treatment was mostly for the domain of academic centers.
“Through this collaboration we will unlock the value of genomics for a much wider group of laboratories and care providers to help them advance genomics initiatives at greater speed with the aim to offer precision medicine with better outcomes for their patients.”
Illumina president and CEO Francis deSouza said: “We believe that this collaboration will provide an excellent path for our next-generation sequencing systems to be incorporated into health systems in the U.S. and worldwide.
“One key strategy in our commitment to improving human health is connecting genomics to the everyday business of healthcare: based on integrated patient data, embedded into clinical pathways, supported by real-world evidence and reimbursement models.”
Image: Philips, Illumina to collaborate on developing genetic solutions for cancer research. Photo: Courtesy of Koninklijke Philips N.V.